DNB Asset Management AS Lowers Position in Hims & Hers Health, Inc. (NYSE:HIMS)

DNB Asset Management AS cut its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 4.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,696 shares of the company’s stock after selling 797 shares during the quarter. DNB Asset Management AS’s holdings in Hims & Hers Health were worth $337,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of HIMS. Forerunner Ventures Management LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter worth approximately $86,836,000. Farallon Capital Management LLC increased its position in shares of Hims & Hers Health by 3,890.5% during the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after acquiring an additional 1,634,000 shares during the last quarter. M&G Plc purchased a new stake in shares of Hims & Hers Health during the first quarter valued at approximately $8,232,000. Mckinley Capital Management LLC increased its position in shares of Hims & Hers Health by 34.9% during the fourth quarter. Mckinley Capital Management LLC now owns 896,020 shares of the company’s stock valued at $7,975,000 after acquiring an additional 231,867 shares during the last quarter. Finally, Quantbot Technologies LP increased its position in shares of Hims & Hers Health by 3,444.9% during the first quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock valued at $3,321,000 after acquiring an additional 208,621 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on HIMS shares. Deutsche Bank Aktiengesellschaft increased their price target on Hims & Hers Health from $14.00 to $16.00 and gave the company a “hold” rating in a research report on Tuesday, May 7th. Citigroup downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating and raised their target price for the stock from $16.00 to $20.00 in a research report on Wednesday, May 22nd. Bank of America raised their target price on Hims & Hers Health from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. Truist Financial raised their target price on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, July 18th. Finally, Seaport Res Ptn reissued a “buy” rating on shares of Hims & Hers Health in a research report on Friday, April 26th. Seven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.07.

Hims & Hers Health Stock Down 4.0 %

NYSE:HIMS traded down $0.68 during trading hours on Wednesday, hitting $16.20. 2,132,614 shares of the company’s stock traded hands, compared to its average volume of 7,759,311. The firm has a market cap of $3.48 billion, a P/E ratio of -1,687.00 and a beta of 1.08. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $25.74. The business’s fifty day simple moving average is $21.35 and its two-hundred day simple moving average is $15.86.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The business had revenue of $315.65 million for the quarter, compared to the consensus estimate of $302.43 million. During the same quarter last year, the business posted ($0.03) earnings per share. The company’s revenue for the quarter was up 51.8% on a year-over-year basis. On average, analysts expect that Hims & Hers Health, Inc. will post 0.2 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,503 shares of the firm’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $12.33, for a total transaction of $30,861.99. Following the sale, the insider now owns 159,357 shares in the company, valued at $1,964,871.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Patrick Harrison Carroll sold 10,000 shares of Hims & Hers Health stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $13.00, for a total value of $130,000.00. Following the transaction, the insider now owns 173,880 shares in the company, valued at $2,260,440. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Soleil Boughton sold 2,503 shares of Hims & Hers Health stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $12.33, for a total value of $30,861.99. Following the completion of the transaction, the insider now owns 159,357 shares in the company, valued at approximately $1,964,871.81. The disclosure for this sale can be found here. Insiders have sold 782,901 shares of company stock worth $16,138,997 over the last 90 days. Corporate insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.